Analysts Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Price Target at $12.33

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $12.3333.

A number of brokerages recently commented on DMAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald assumed coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They set an “overweight” rating on the stock. TD Cowen started coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating for the company. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Finally, Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

DiaMedica Therapeutics Trading Down 0.7%

DiaMedica Therapeutics stock opened at $8.30 on Friday. The firm has a market cap of $432.24 million, a P/E ratio of -11.69 and a beta of 1.11. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $10.42. The firm has a 50-day moving average of $8.36 and a 200-day moving average of $7.14.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Research analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Transactions at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg acquired 240,352 shares of the stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $7.21 per share, with a total value of $1,732,937.92. Following the completion of the transaction, the insider owned 8,375,092 shares of the company’s stock, valued at $60,384,413.32. This represents a 2.95% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 1,061,277 shares of company stock valued at $7,632,627 in the last ninety days. 7.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DMAC. Los Angeles Capital Management LLC bought a new stake in DiaMedica Therapeutics during the fourth quarter worth about $183,000. Goldman Sachs Group Inc. lifted its holdings in shares of DiaMedica Therapeutics by 67.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 129,388 shares of the company’s stock valued at $1,030,000 after purchasing an additional 52,096 shares during the last quarter. AXQ Capital LP bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth approximately $96,000. Intech Investment Management LLC boosted its position in shares of DiaMedica Therapeutics by 32.5% in the 4th quarter. Intech Investment Management LLC now owns 18,460 shares of the company’s stock worth $147,000 after purchasing an additional 4,525 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock worth $6,085,000 after buying an additional 52,437 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.